Literature DB >> 19111451

Metabolic syndrome and prostate cancer: a review.

J P Nobes1, S E M Langley, R W Laing.   

Abstract

Androgen deprivation therapy is widely used in a number of different settings in the treatment of prostate cancer. This overview will look at the current evidence for the potential development of metabolic syndrome and cardiovascular disease as a consequence of this therapy, and highlight strategies aimed at their prevention. The relationship between metabolic syndrome and prostate cancer development will also be examined.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19111451     DOI： 10.1016/j.clon.2008.11.013

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


  8 in total

Review 1.  The fat side of prostate cancer.

Authors:  Giorgia Zadra; Cornelia Photopoulos; Massimo Loda
Journal:  Biochim Biophys Acta       Date:  2013-04-02

2.  Prostate cancer gene expression signature of patients with high body mass index.

Authors:  S Sharad; A Srivastava; S Ravulapalli; P Parker; Y Chen; H Li; G Petrovics; A Dobi
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-11-09       Impact factor: 5.554

3.  Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer.

Authors:  A Spitz; J M Young; L Larsen; C Mattia-Goldberg; J Donnelly; K Chwalisz
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-10-25       Impact factor: 5.554

Review 4.  Metabolic effects of androgen deprivation therapy.

Authors:  See Min Choi; Sung Chul Kam
Journal:  Korean J Urol       Date:  2015-01-06

5.  Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.

Authors:  Cecilia Bosco; Danielle Crawley; Jan Adolfsson; Sarah Rudman; Mieke Van Hemelrijck
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 6.  Hormone naïve prostate cancer: predicting and maximizing response intervals.

Authors:  Judd W Moul
Journal:  Asian J Androl       Date:  2015 Nov-Dec       Impact factor: 3.285

7.  Lipogenic metabolism: a viable target for prostate cancer treatment?

Authors:  Mengmeng Liang; David J Mulholland
Journal:  Asian J Androl       Date:  2014 Sep-Oct       Impact factor: 3.285

8.  Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice.

Authors:  Anki Knutsson; Sabrina Hsiung; Selvi Celik; Sara Rattik; Ingrid Yao Mattisson; Maria Wigren; Howard I Scher; Jan Nilsson; Anna Hultgårdh-Nilsson
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.